Table 2.

Constitutive Tumorigenesis in Squamous Cell Carcinomas Affected by Major Oncogenic Pathway

Tumorigenesis5-Aza-dCPI3K Inhibitor*Erk Inhibitor†Rapamycin
TE1++−−+++
TE2−−−−NA
TE4+−−+−
TE5−−−−NA
KYSE30++−++
KYSE150++−++
KYSE200++−−+++
KYSE410+−−++
KYSE520−−−−NA
011−−−−NA
012−−−−NA
013+−−+NA
019+−−++NA
022+−−+NA
028+−−++NA
Fadu+−−++NA
SCC15−−−−NA

  • Abbreviations: PI3K, phosphatidylinositol 3-kinase; Erk, extracellular signal–regulated kinase.

  • ↵* LY294002 was used as a specific phosphatidylinositol 3-kinase inhibitor.

  • ↵† PD 98059 was used as a specific extracellular signal–regulated kinase inhibitor.